Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication

Internal Medicine

Volumn 52, Issue 17, 2013, Pages 1855-1862

  Kinoshita, Hiroto ^a   Kunisaki, Reiko ^a   Yamamoto, Hisae ^a   Matsuda, Reikei ^a   Sasaki, Tomohiko ^a   Kimura, Hideaki ^a   Tanaka, Katsuaki ^a   Naganuma, Makoto ^b   Maeda, Shin ^c  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Fulminant disease; Infliximab; Infusion interval; Intestinal Beh et's disease; Prednisolone; Tumor necrosis factor and alpha;

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; COLCHICINE; INFLIXIMAB; MESALAZINE; PREDNISOLONE;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLONOSCOPY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFUSION RELATED REACTION; LOW DRUG DOSE; MALE; PERFORATION; PERITONITIS; PREDICTION; RECURRENT DISEASE; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883319786     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.0589     Document Type: Article

References (23)

1. Verity DH, Wallace GR, Vaughan RW, Stanford MR. Behçet's disease: from Hippocrates to the third millennium. Br J Ophthalmol 87: 1175-1183, 2003.
2. Kobayashi K, Ueno F, Bito S, et al. Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach. J Gastroenterol 42: 737-745, 2007.
3. Jung YS, Yoon JY, Lee JH, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behçet's disease. Inflamm Bowel Dis 17: 1594-1602, 2011.
4. Naganuma M, Iwao Y, Inoue N, et al. Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behçet's disease. Am J Gastroenterol 95: 2848-2851, 2000.
5. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 106: 644-659, quiz 660, 2011.
6. Mendes D, Correia M, Barbedo M, et al. Behçet's disease-a contemporary review. J Autoimmun 32: 178-188, 2009.
7. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 49: 725-728, 2001.
8. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology 120: 995-999, 2001.
9. Kram MT, May LD, Goodman S, Molinas S. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 46: 118-121, 2003.
10. Ju JH, Kwok SK, Seo SH, Yoon CH, Kim HY, Park SH. Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab. Clin Rheumatol 26: 1383-1385, 2007.
11. Byeon JS, Choi EK, Heo NY, et al. Antitumor necrosis factoralpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case. Dis Colon Rectum 50: 672-676, 2007.
12. Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis 14: 1259-1264, 2008.
13. Iwata S, Saito K, Yamaoka K, et al. Efficacy of combination therapy of anti-TNF-alpha antibody infliximab and methotrexate in refractory entero-Behçet's disease. Mod Rheumatol 21: 184-191, 2011.
14. Cheon JH, Han DS, Park JY, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behçet's disease. Inflamm Bowel Dis 17: 605-613, 2011.
15. Chung MJ, Cheon JH, Kim SU, et al. Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behçet disease. J Clin Gastroenterol 44: e116-e122, 2010.
16. Yasui K, Uchida N, Akazawa Y, et al. Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease. Inflamm Bowel Dis 14: 396-400, 2008.
17. Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41: 61-70, 2011.
18. Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet 42: 703-706, 2010.
19. Franke A, McGovern DP, Barrett JC, et al. Genome-wide metaanalysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 42: 1118-1125, 2010.
20. Ando Y, Matsushita M, Kawamata S, Shimatani M, Fujii T, Okazaki K. Infliximab for severe gastrointestinal bleeding in Crohn's disease. Inflamm Bowel Dis 15: 483-484, 2009.
21. Meyer MM, Levine EJ. Acute hemorrhagic Crohn's disease controlled with infliximab. Inflamm Bowel Dis 15: 1456-1457, 2009.
22. Ordas I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut 60: 1754-1763, 2011.
23. Kotter I, Gunaydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications-results of a retrospective analysis of 117 cases. Clin Rheumatol 25: 482-486, 2006.